Literature DB >> 17158032

Long-term evolution of EEG in Unverricht-Lundborg disease.

Edoardo Ferlazzo1, Adriana Magaudda, Pasquale Striano, Nguyen Vi-Hong, Salvatore Serra, Pierre Genton.   

Abstract

PURPOSE: Unverricht-Lundborg disease (ULD) is a progressive myoclonus epilepsy characterized by myoclonus, epilepsy, and ataxia, without major cognitive decline. There is no systematic study on the long-term evolution of EEG in this condition. PATIENTS AND METHODS: Twenty-five patients with ULD who came to our observation before 1995 and periodically followed in our Epilepsy Centres were included. All waking EEG traces were visually reviewed for the characterization background activity, with particular regard to the frequency of the posterior dominant rhythm (PR), and for the occurrence of spontaneous generalized spike or polyspike and wave discharges (GSWD) and photoparoxysmal response (PPR). Sleep recordings were analyzed with particular regard to the preservation of the physiological sleep patterns and the occurrence of GSWD and other epileptic abnormalities.
RESULTS: PR was normal in 68% of patients at the beginning of the disease and kept stable over the years. GSWD were present in 92% of patients at the onset of the disease and gradually disappeared during the follow-up with a significant difference (p<0.001) after the 15th year of disease. PPR was present in 88% of patients at the disease onset and gradually disappeared with a significant difference (p<0.001) after the 10th year of disease. A gradual reduction of GSWD and a progressive disappearance of physiological sleep patterns were observed in sleep EEGs.
CONCLUSION: In patients with ULD followed for an extended period of time, EEG shows no relevant deterioration of BA while a gradual reduction of GSWD and PPR is observed over time, well correlating with the good seizure outcome in this condition.

Entities:  

Mesh:

Year:  2006        PMID: 17158032     DOI: 10.1016/j.eplepsyres.2006.10.006

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

Review 1.  Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies.

Authors:  Edoardo Ferlazzo; Dorothee Kasteleijn-Nolst Trenite; Gerrit-Jan de Haan; Felix Felix Nitschke; Saija Ahonen; Sara Gasparini; Berge A Minassian
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

2.  FDG-PET findings and alcohol-responsive myoclonus in a patient with Unverricht-Lundborg disease.

Authors:  Lorenzo Muccioli; Andrea Farolfi; Federica Pondrelli; Eleonora Matteo; Lorenzo Ferri; Laura Licchetta; Lara Alvisi; Paolo Tinuper; Francesca Bisulli
Journal:  Epilepsy Behav Rep       Date:  2022-05-13

3.  Progressive myoclonic epilepsy type 1: Report of an Emirati family and literature review.

Authors:  Mohammed Saadah; Mahfoud El Beshari; Loai Saadah; Hisham Hamdallah; Zeinab Alloub; Amani Ali Al Zaabi; Abdelmatlob Ben-Mussa; Anwaar Ben-Nour
Journal:  Epilepsy Behav Case Rep       Date:  2014-05-04

4.  Case Report: Distinctive EEG Patterns in SCARB-2 Related Progressive Myoclonus Epilepsy.

Authors:  Mostafa Hotait; Maya Dirani; Tarek El Halabi; Ahmad Beydoun
Journal:  Front Genet       Date:  2020-12-03       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.